Basic Information | Post buying leads | Suppliers | Cas Database |
Conditions | Yield |
---|---|
With C14H14B2(2-)*2Li(1+) In tetrahydrofuran at 25℃; under 760.051 Torr; Sealed tube; Cooling with liquid nitrogen; Inert atmosphere; | 83% |
With Tri-n-octylamine; water; lithium chloride In butan-1-ol under 7.50075E-06 Torr; | |
With lithium hydroxide monohydrate In water for 2.68333h; Kinetics; Time; | |
With C2H3OS2(1-)*Li(1+) In methanol |
Conditions | Yield |
---|---|
In tetrahydrofuran reductive disproportionation; mechanism discussed;; IR;; | A 82% B 74% |
In tetrahydrofuran soln. of the W-compound was treated with gasous CO2 at -78°C, warmed to 25°C; solvent removed (vac.), extd. (diethyl ether), ether removed (vac.); IR, MAS; | A 82% B 74% |
Conditions | Yield |
---|---|
In not given pptn. from concd. LiCl soln. with excess of K2CO3;; | |
In not given pptn. from concd. LiCl soln. with excess of K2CO3;; |
Conditions | Yield |
---|---|
In not given pptn. from concd. LiNO3 soln. with excess of K2CO3;; | |
In not given pptn. from concd. LiNO3 soln. with excess of K2CO3;; |
Conditions | Yield |
---|---|
In not given | |
In not given pptn. from concd. Li2SO4 soln. with excess of K2CO3;; | |
In not given | |
In not given pptn. from concd. Li2SO4 soln. with excess of K2CO3;; |
lithium acetate dihydrate
lithium carbonate
Conditions | Yield |
---|---|
With poly(methyl methacrylate); oxalic acid; Ni(CH3COO)2*4H2O In methanol byproducts: NiO; poly(methyl methacrylate) added; pptd. by adding of oxalic acid soln.; calcined at 298-400°C for 1-15 h in mixed atm. air/N2, at 400-600°C in air or O2; powder XRD; | |
In neat (no solvent, solid phase) heated for 1 h at 500°C; XRD; |
lithium acetate dihydrate
nickel(II) acetate tetrahydrate
A
nickel(II) oxide
C
lithium carbonate
Conditions | Yield |
---|---|
In water mixt. stirred, heated at 120 °C to remove water, heated at 250 °C for 24 h or at 370 °C for 24 h; detd. by XRD; |
lithium hydroxide monohydrate
nickel(II) acetate tetrahydrate
A
nickel(II) oxide
B
lithium carbonate
Conditions | Yield |
---|---|
In neat (no solvent) LiOH*H2O and Ni acetate separately dissolved in H2O; mixed; pH adjusted to 8.5-9.5; heated at 110°C until they were dry; calcined at 300-500°C; monitored by X-ray diffraction; |
lithium hydroxide monohydrate
nickel(II) acetate tetrahydrate
B
lithium carbonate
Conditions | Yield |
---|---|
In neat (no solvent) LiOH*H2O and Ni acetate separately dissolved in H2O; mixed; pH adjusted to 8.5-9.5; heated at 110°C until they were dry; calcined at 600°C; monitored by X-ray diffraction; |
Conditions | Yield |
---|---|
High Pressure; at 400°C, pressure of CO2: 2100 at for 6 h; |
Lithium carbonate, its cas register number is 554-13-2. It also can be called Lithonate; Lithium hydroxide, solution; Eskalith; and Lithobid. Lithium carbonate, the most widely used of the compounds, is employed in the production of lithium metal and ft-its and enamels. Together with lithium fluoride (LiF), it serves as an additive for cryolite in the elec-trolytic pot line production of primary aluminum. It also is used to treat manic states and bipolar disorder, and is used in the manufacture of most LITHIUM-ion battery cathodes, which are made of lithlum cobalt oxide. It is manufactured from spodumene, which is by far the most important lithium-containing ore.
Physical properties about Lithium carbonate are: (1)ACD/LogP: -0.809; (2)ACD/LogD (pH 5.5): -1.98; (3)ACD/LogD (pH 7.4): -3.77; (4)ACD/BCF (pH 5.5): 1.00; (5)ACD/BCF (pH 7.4): 1.00; (6)ACD/KOC (pH 5.5): 1.00; (7)ACD/KOC (pH 7.4): 1.00; (8)#H bond acceptors: 3; (9)#H bond donors: 2; (10)Flash Point: 169.8 °C; (11)Enthalpy of Vaporization: 63.37 kJ/mol; (12)Boiling Point: 333.6 °C at 760 mmHg; (13)Vapour Pressure: 2.58E-05 mmHg at 25°C
You can still convert the following datas into molecular structure:
(1)InChI=1S/CH2O3.2Li/c2-1(3)4;;/h(H2,2,3,4);;/q;2*+1/p-2;
(2)InChIKey=XGZVUEUWXADBQD-UHFFFAOYSA-L;
(3)SmilesC(=O)([O-])[O-].[Li+].[Li+];
The toxicity data is as follows:
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
dog | LD50 | oral | 500mg/kg (500mg/kg) | "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972Vol. -, Pg. 436, 1972. | |
human | TDLo | oral | 4111mg/kg (4111mg/kg) | GASTROINTESTINAL: OTHER CHANGES BEHAVIORAL: TREMOR BEHAVIORAL: MUSCLE WEAKNESS | New England Journal of Medicine. Vol. 287, Pg. 867, 1972. |
man | TDLo | oral | 8mg/kg (8mg/kg) | GASTROINTESTINAL: NAUSEA OR VOMITING SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" | American Journal of Psychiatry. Vol. 141, Pg. 909, 1984. |
man | TDLo | oral | 54mg/kg (54mg/kg) | BEHAVIORAL: SLEEP BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" | New Zealand Medical Journal. Vol. 97, Pg. 23, 1984. |
man | TDLo | oral | 1080mg/kg/13W (1080mg/kg) | SKIN AND APPENDAGES (SKIN): "DERMATITIS, ALLERGIC: AFTER SYSTEMIC EXPOSURE" | Journal of Clinical Psychiatry. Vol. 47, Pg. 330, 1986. |
man | TDLo | oral | 25gm/kg/4Y-I (25000mg/kg) | BEHAVIORAL: TREMOR SENSE ORGANS AND SPECIAL SENSES: MIOSIS (PUPILLARY CONSTRICTION): EYE | Journal of Clinical Psychiatry. Vol. 46, Pg. 292, 1985. |
mouse | LD50 | intraperitoneal | 236mg/kg (236mg/kg) | BEHAVIORAL: ATAXIA BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: EXCITEMENT | Kiso to Rinsho. Clinical Report. Vol. 7, Pg. 1273, 1973. |
mouse | LD50 | intravenous | 497mg/kg (497mg/kg) | LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) | Kiso to Rinsho. Clinical Report. Vol. 7, Pg. 1273, 1973. |
mouse | LD50 | oral | 531mg/kg (531mg/kg) | Russian Pharmacology and Toxicology Vol. 33, Pg. 266, 1970. | |
mouse | LD50 | subcutaneous | 413mg/kg (413mg/kg) | Russian Pharmacology and Toxicology Vol. 33, Pg. 266, 1970. | |
rat | LD50 | intraperitoneal | 156mg/kg (156mg/kg) | GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) | Kiso to Rinsho. Clinical Report. Vol. 7, Pg. 1273, 1973. |
rat | LD50 | intravenous | 241mg/kg (241mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION | Kiso to Rinsho. Clinical Report. Vol. 7, Pg. 1273, 1973. |
rat | LD50 | oral | 525mg/kg (525mg/kg) | LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" | Kiso to Rinsho. Clinical Report. Vol. 7, Pg. 1273, 1973. |
rat | LD50 | subcutaneous | 434mg/kg (434mg/kg) | SENSE ORGANS AND SPECIAL SENSES: LACRIMATION: EYE LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION SKIN AND APPENDAGES (SKIN): HAIR: OTHER | Kiso to Rinsho. Clinical Report. Vol. 7, Pg. 1273, 1973. |
women | TDLo | oral | 120mg/kg/10D- (120mg/kg) | BEHAVIORAL: EXCITEMENT | Journal of Clinical Psychiatry. Vol. 48, Pg. 81, 1987. |
women | TDLo | oral | 612mg/kg/44D- (612mg/kg) | SKIN AND APPENDAGES (SKIN): "DERMATITIS, ALLERGIC: AFTER SYSTEMIC EXPOSURE" BEHAVIORAL: SLEEP | American Journal of Psychiatry. Vol. 152, Pg. 956, 1995. |
women | TDLo | oral | 8760mg/kg/2Y- (8760mg/kg) | ENDOCRINE: EVIDENCE OF THYROID HYPERFUNCTION ENDOCRINE: THYROID WEIGHT (GOITER) | American Journal of Medicine. Vol. 99, Pg. 575, 1995. |
women | TDLo | oral | 36500mg/kg/10 (36500mg/kg) | ENDOCRINE: DIABETES INSIPIDUS (NEPHROGENIC OR CNS) KIDNEY, URETER, AND BLADDER: URINE VOLUME INCREASED KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" | Annales de Medecine Interne. Vol. 148, Pg. 284, 1997. |
women | TDLo | unreported | 556mg/kg/32D (556mg/kg) | BEHAVIORAL: TOXIC PSYCHOSIS | JAMA, Journal of the American Medical Association. Vol. 213, Pg. 865, 1970. |